Genentech announced the results for its investigational medicine entrectinib, from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1, and phase I ALKA trials, which showed that entrectinib shrank tumors (objective response rate) in 77.4 percent of people with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
